Much has been said of Allergy Therapeutics ' (AGY) Pollinex Quattro hay fever vaccine and its potential launch in the US. But in recent weeks, the Alternative Investment Market (Aim)-traded group has proved it is not merely a one-trick pony.
Since the start of February, Allergy has reported positive data for both its house mite allergy vaccine - Acarovac Quattro - and its peanut allergy vaccine, Polyvac Peanut. This means the company now expects to start Phase I clinical studies immediately in order to assess the safety and tolerability in various doses. The group raised money in November 2015 in order to fund its pipeline and, so far, progress has been on schedule. If the upcoming Phase I trial is successful, Allergy expects to launch Acarovac Quattro in Spain on a named-patient basis.
